Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

U.S. FDA Foreign Inspections User Fee Program Getting Push From Congress

This article was originally published in PharmAsia News

Executive Summary

The pharmaceutical industry is facing an increasingly aggressive push to create user fees for manufacturing inspections

You may also be interested in...



Foreign Regulator Exchange Program Contemplated By U.S. State Department

FDA has its own programs, but a State Department undersecretary said enhancing training at FDA could boost efforts to fight drug counterfeiting and diversion.

BIO’s "Big Ideas" For FDA Reform Are Too Big For PDUFA

FDA Looks To Capitol Hill For New Authority For Globalization Plan

Legislative fixes are required for U.S. FDA to implement its long-term strategy to use a coalition of regulators to secure the world drug supply chain, but the agency says it will not let that stop it from implementing its Pathway to Global Product Safety and Quality plan

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

SC078682

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel